255 Appendices A 15. Das SR, Xie L, Wisse LE, Ittyerah R, Tustison NJ, Dickerson BC, et al. Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake. Neurobiology of aging. 2018;66:49-58. 16. Sintini I, Martin PR, Graff-Radford J, Senjem ML, Schwarz CG, Machulda MM, et al. Longitudinal tau-PET uptake and atrophy in atypical Alzheimer’s disease. NeuroImage: Clinical. 2019;23:101823. 17. Xu G, Zheng S, Zhu Z, Yu X, Jiang J, Jiang J, et al. Association of tau accumulation and atrophy in mild cognitive impairment: a longitudinal study. Annals of Nuclear Medicine. 2020;34:815-23. 18. Sojkova J, Beason-Held L, Zhou Y, An Y, Kraut MA, Ye W, et al. Longitudinal cerebral blood flow and amyloid deposition: an emerging pattern? Journal of Nuclear Medicine. 2008;49:1465-71. 19. Ebenau JL, Visser D, Verfaillie SC, Timmers T, van Leeuwenstijn MS, Kate Mt, et al. Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals. European Journal of Nuclear Medicine and Molecular Imaging. 2023;50:410-22. 20. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology. 1992;42:631-. 21. Aschenbrenner AJ, Gordon BA, Benzinger TL, Morris JC, Hassenstab JJ. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology. 2018;91:e859-e66. 22. Smith R, Hägerström D, Pawlik D, Klein G, Jögi J, Ohlsson T, et al. Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms. JAMA neurology. 2023. 23. Altomare D, Caprioglio C, Assal F, Allali G, Mendes A, Ribaldi F, et al. Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. European journal of nuclear medicine and molecular imaging. 2021;48:2200-11. 24. Mattsson-Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE, et al. Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO molecular medicine. 2021;13:e14022. 25. Ossenkoppele R, Reimand J, Smith R, Leuzy A, Strandberg O, Palmqvist S, et al. Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers. EMBO molecular medicine. 2021;13:e14398. 26. Smith R, Cullen NC, Pichet Binette A, Leuzy A, Blennow K, Zetterberg H, et al. Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients. Alzheimer’s & Dementia. 2023;19:2497-507. 27. Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer’s disease. New England Journal of Medicine. 2021;384:1691704. 28. Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous Sr MD, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimer’s & dementia. 2015;11:1-15. e4.
RkJQdWJsaXNoZXIy MjY0ODMw